Abbott Laboratories vs BlackBerry Limited — how do they compare? Abbott Laboratories trades at $109.64 (market cap $187.95B), while BlackBerry Limited trades at $8.99 (market cap $5.18B). The key difference: Abbott Laboratories is far larger — about 36.3× BlackBerry Limited's market cap, and Abbott Laboratories pays a 2.32% dividend while BlackBerry Limited pays none. Which is the better fit depends on your goals.
| ABT | BB | |
|---|---|---|
Market Cap | $187.95B | $5.18B |
Sector | Health | Technology |
52-Week High | $136.62 | $12.81 |
52-Week Low | $82.57 | $3.15 |
Enterprise Value | $214.96B | $5.05B |
Dividend Yield | 2.32% | — |
Signals from Pluang's Aura AI — not financial advice
Abbott Laboratories (ABT) trades at $107.80, down slightly by 0.14% today. The stock shows a bullish technical signal with strong moving average support and a consensus analyst price target of $120.70. Recent earnings beat expectations in Q1 and Q2 2026, while revenue grew to $44.33 billion in 2025. The company secured a CE Mark for its Libre Duo glucose-ketone sensor, highlighting innovation in diabetes care.
The outlook remains positive given analyst consensus and recent product approvals, but risks include competitive pressures and macroeconomic volatility. Upside potential exists if earnings momentum continues, though valuation multiples are above industry averages, warranting caution on significant expansion.
BlackBerry (BB) trades at $8.98, up 2.28% today, with a bullish technical signal from moving averages but mixed oscillators. Recent earnings beats and a positive 2026 net income forecast of $60M signal a turnaround, though 2025 saw a net loss of $79M. The stock's valuation remains elevated with a P/E of 89.8 and P/S of 9.22. News highlights growth in QNX and secure communications, with the stock gaining 125% year-to-date as of August 2026, though it has pulled back 35% from its peak.
The outlook hinges on execution of growth in QNX and secure communications, with FY2027 guidance suggesting 11% revenue growth and 20% adjusted EBITDA margin expansion. Risks include premium valuation, cyclical industry exposure, and reliance on long-dated QNX royalties. Analyst consensus is cautious with 85.7% hold ratings, but a $10.50 price target implies potential upside if operational improvements materialize.
Trailing returns across standard periods
Latest headlines on both assets
Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Read more on ABT →BlackBerry Limited provides intelligent security software solutions. The Company offers artificial intelligence and machine learning for cybersecurity, safety, and data privacy solutions, as well as endpoint security and management, encryption, and embedded systems. BlackBerry serves governments and enterprise sectors worldwide.
Read more on BB →